New concepts in adrenal vein sampling for aldosterone in the diagnosis of primary aldosteronism

Current Hypertension Reports

Volumn 9, Issue 2, 2007, Pages 90-97

  Rossi, Gian Paolo ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

6BETA IODOMETHYL 19 NORCHOLEST 5(10) EN 3BETA OL I 131; ALDOSTERONE; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CORTICOTROPIN; CYCLOOXYGENASE 1 INHIBITOR; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCORTISONE; IODINE 131; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; VASODILATOR AGENT;

ADRENAL CORTEX; ADRENAL CORTEX ADENOMA; ADRENAL HYPERPLASIA; ADRENAL SCINTISCANNING; ADRENAL VEIN SAMPLING; ADRENALECTOMY; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE RELEASE; BLOOD SAMPLING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FOLLOW UP; GENETIC DISORDER; GOLD STANDARD; GYNECOMASTIA; HEREDITARY HYPERTENSION; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERTENSION; IMPOTENCE; INCIDENTAL FINDING; INFERIOR CAVA VEIN; LIBIDO DISORDER; NORMAL VALUE; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMERASE CHAIN REACTION; PRIMARY HYPERALDOSTERONISM; REVIEW; SENSITIVITY AND SPECIFICITY; TUMOR DIAGNOSIS;

ADRENAL GLANDS; ALDOSTERONE; BLOOD PRESSURE; DIAGNOSIS, DIFFERENTIAL; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; VEINS;

EID: 34249105835     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-007-0017-3     Document Type: Review

References (52)

1. Rossi GP, Bernini G, Caliumi C, et al.: for the PAPY Study Investigators: A prospective study of the prevalence of primary aldosteronism in 1125 hypertensive patients. J Am Coll Cardiol 2006, 48:2293-2300.
2. Rayner BL, Opie LH, Davidson JS: The aldosterone/renin ratio as a screening test for primary aldosteronism. S Afr Med J 2000, 90:394-400.
3. Rossi E, Regolisti G, Negro A, et al.: High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. Am J Hypertens 2002, 15:896-902.
4. Schwartz GL, Chapman AB, Boerwinkle E, et al.: Screening for primary aldosteronism: implications of an increased plasma aldosterone/renin ratio. Clin Chem 2002, 48:1919-1923.
5. Rossi GP, Rossi E, Pavan E, et al.: Screening for primary aldosteronism with a logistic multivariate discriminant analysis. Clin Endocrinol (Oxf) 1998, 49:713-723.
6. Rossi GP: Surgically correctable hypertension caused by primary aldosteronism. Best Pract Res Clin Endocr Metab 2006, 20:385-400.
7. Mannhart M, Ludin H, Veyrat R, Ziegler WH: Secondary hyperaldosteronism caused by cervical phaeochromocytoma cured by ablation of the tumor. Helv Med Acta 1971, 35:479-483.
8. Kitajima W, Saruta T, Kondo K, et al.: A case of secondary aldosteronism induced by pheochromocytoma. J Urol 1975, 114:141-143.
9. Wajiki M, Ogawa A, Fukui J, et al.: Coexistence of aldosteronoma and pheochromocytoma in an adrenal gland. J Surg Oncol 1985, 28:75-78.
10. Gordon RD, Bachmann AW, Klemm SA, et al.: An association of primary aldosteronism and adrenaline-secreting phaeochromocytoma. Clin Exp Pharmacol Physiol 1994, 21:219-222.
11. Tan GH, Carney JA, Grant CS, Young WF, Jr: Coexistence of bilateral adrenal phaeochromocytoma and idiopathic hyperaldosteronism. Clin Endocrinol (Oxf) 1996, 44:603-609.
12. Stowasser M, Klemm SA, Tunny TJ, et al.: Response to unilateral adrenalectomy for aldosterone-producing adenoma: effect of potassium levels and angiotensin responsiveness. Clin Exp Pharmacol Physiol 1994, 21:319-322.
13. Omura M, Sasano H, Fujiwara T, et al.: Unique cases of unilateral hyperaldosteronemia due to multiple adrenocortical micronodules, which can only be detected by selective adrenal venous sampling. Metabolism 2002, 51:350-355.
14. Morioka M, Kobayashi T, Sone A, et al.: Primary aldosteronism due to unilateral adrenal hyperplasia: report of two cases and review of the literature. Endocr J 2000, 47:443-449.
15. Katayama Y, Takata N, Tamura T, et al.: A case of primary aldosteronism due to unilateral adrenal hyperplasia. Hypertens Res 2005, 28:379-384.
16. Rossi GP, Zanin L, De Toni R, et al.: Dopaminergic regulation of aldosterone secretion in primary aldosteronism: a clinical study. Hypertens Res 1994, 17:105-115.
17. Mulatero P, Dluhy RG, Giacchetti G, et al.: Diagnosis of primary aldosteronism: from screening to subtype differentiation. Trends Endocrinol Metab 2005, 16:114-119.
18. Rossi GP, Ganzaroli C, Miotto D, et al.: Dynamic testing with high-dose adrenocorticotrophic hormone does not improve lateralization of aldosterone oversecretion in primary aldosteronism patients. J Hypertens 2006, 24:371-379.
19. Fallo F, Barzon L, Boscaro M, Sonino N: Coexistence of aldosteronoma and contralateral nonfunctioning adrenal adenoma in primary aldosteronism. Am J Hypertens 1997, 10:476-478.
20. Magill SB, Raff H, Shaker JL, et al.: Comparison of adrenal vein sampling and computed tomography in the differentiation of primary aldosteronism. J Clin Endocrinol Metab 2001, 86:1066-1071.
21. Kloos RT, Gross MD, Francis IR, et al.: Incidentally discovered adrenal masses. Endocr Rev 1995, 16:460-484.
22. Mantero F, Terzolo M, Arnaldi G, et al.: A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 2000, 85:637-644.
23. Blumenfeld JD, Sealey JE, Schlussel Y, et al.: Diagnosis and treatment of primary hyperaldosteronism. Ann Intern Med 1994, 121:877-885.
24. Stowasser M, Gordon RD, Rutherford JC, et al.: Diagnosis and management of primary aldosteronism. J Renin Angiotensin Aldosterone Syst 2001, 2:156-169.
25. Young WF, Jr: Primary aldosteronism: management issues. Ann N Y Acad Sci 2002, 970:61-76.
26. Rossi GP, Chiesura-Corona M, Tregnaghi A, et al.: Imaging of aldosterone-secreting adenomas: a prospective comparison of computed tomography and magnetic resonance imaging in 27 patients with suspected primary aldosteronism. J Hum Hypertens 1993, 7:357-363.
27. Lockhart ME, Smith JK, Kenney PJ: Imaging of adrenal masses. Eur J Radiol 2002, 41:95-112.
28. Gordon RD: Primary aldosteronism. J Endocrinol Invest 1995, 18:495-511.
29. Young WF Jr, Stanson AW, Grant CS, et al.: Primary aldosteronism: adrenal venous sampling. Surgery 1996, 120:913-919.
30. Phillips JL, Walther MM, Pezzullo JC, et al.: Predictive value of preoperative tests in discriminating bilateral adrenal hyperplasia from an aldosterone-producing adrenal adenoma. J Clin Endocrinol Metab 2000, 85:4526-4533.
31. Rossi GP, Sacchetto A, Chiesura-Corona M, et al.: Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance findings: results in 104 consecutive cases. J Clin Endocrinol Metab 2001, 86:1083-1090.
32. Young WF, Stanson AW, Thompson GB, et al.: Role for adrenal venous sampling in primary aldosteronism. Surgery 2004, 136:1227-1235.
33. Daunt N: Adrenal vein sampling: how to make it quick, easy, and successful. Radiographics 2005, 25(Suppl 1): S143-S158.
34. Enberg U, Volpe C, Hong A, et al.: Postoperative differentiation between unilateral adrenal adenoma and bilateral adrenal hyperplasia in primary aldosteronism by mRNA expression of the gene CYP11B2. Eur J Endocrinol 2004, 151:73-85.
35. Espiner EA, Ross DG, Yandle TG, et al.: Predicting surgically remedial primary aldosteronism: role of adrenal scanning, posture testing, and adrenal vein sampling. J Clin Endocrinol Metab 2003, 88:3637-3644.
36. Rossi GP, Pitter G, Miotto D: To stimulate or not to stimulate: is adrenocorticotrophic hormone testing necessary, or not? J Hypertens 2007, 25:481-484.
37. 131I-19-iodocholesterol. N Engl J Med 1976, 294:410-414.
38. Nomura K, Kusakabe K, Maki M, et al.: Iodomethylnorcholesterol uptake in an aldosteronoma shown by dexamethasone-suppresion scintigraphy: relationship to adenoma size and functional activity. J Clin Endocrinol Metab 1990, 71:825-830.
39. Gross MD, Shapiro B, Freitas JE: Limited significance of asymmetric adrenal visualization on dexamethasone-suppression scintigraphy. J Nucl Med 1985, 26:43-48.
40. Vetter H, Fischer M, Galanski M, et al.: Primary aldosteronism: diagnosis and noninvasive lateralization procedures. Cardiology 1985, 72(Suppl 1):57-63.
41. Gordon RD: Primary aldosteronism. J Endocrinol Invest 1995, 18:495-511.
42. Mansoor GA, Malchoff CD, Arici MH, et al.: Unilateral adrenal hyperplasia causing primary aldosteronism: limitations of I-131 norcholesterol scanning. Am J Hypertens 2002, 15:459-464.
43. Bossuyt PM, Reitsma JB, Bruns DE, et al.: The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin Chem 2003, 49:7-18.
44. Diaz-Cano SJ, de Miguel M, Blanes A, et al.: Clonality as expression of distinctive cell kinetics patterns in nodular hyperplasias and adenomas of the adrenal cortex. Am J Pathol 2000, 156:311-319.
45. Rossi GP, Vendraminelli R, Cesari M, Pessina AC: A thoracic mass with hypertension and hypokalaemia. Lancet 2000, 356:1570.
46. Seccia TM, Fassina A, Nussdorfer GG, et al.: Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn's syndrome with an ominous clinical course. Endocr Relat Cancer 2005, 12:149-159.
47. Wolf-Maier K, Cooper RS, Banegas JR, et al.: Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003, 289:2363-2369.
48. Rundback JH, Sacks D, Kent KC, et al.: Guidelines for the reporting of renal artery revascularization in clinical trials. American Heart Association. Circulation 2002, 106:1572-1585.
49. Dluhy RG, Lifton RP: Glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 1999, 84:4341-4344.
50. Mulatero P, Veglio F, Pilon C, et al.: Diagnosis of glucocorticoid-remediable aldosteronism in primary aldosteronism: aldosterone response to dexamethasone and long polymerase chain reaction for chimeric gene. J Clin Endocrinol Metab 1998, 83:2573-2575.
51. Pascoe L, Jeunemaitre X, Lebrethon MC, et al.: Glucocorticoid-suppressible hyperaldosteronism and adrenal tumors occurring in a single French pedigree. J Clin Invest 1995, 96:2236-2246.
52. Milliez P, Girerd X, Plouin PF, et al.: Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005, 45:1243-1248.